“Medication-Free Research in Early Episode Schizophrenia: Evidence of Long-Term Harm?” An article in the Schizophrenia Bulletin, by Dr. John Bola that dares to question the validity of the unexamined treatment paradigm in schizophrenia:
The focus of a recent FDA’s Psychopharmacology Advisory Committee meeting, was the drug, modafinil (as Sparlon), for ADHD and the risk of
Steven-Johnson’s, a rare but potentially fatal, skin condition.
"That thing I’m worried about…where the MedGuide would help, where it might even warrant a black box, if this is common, where somebody hallucinates and then gets put on an anti-psychotic drug. That would really be something worth making sure it doesn’t happen,"
On Wednesday, the FDA Pediatric Advisory Committee handed the agency a mixed message regarding warnings about selective list of
psychotropic drugs prescribed for treating ADHD symptoms.
AHRP Urges Actions to Minimize Risks for Children prescribed psychotropic drugs: Action is needed to protect children from widespread prescribing of psychoactive drugs for ill-defined behavioral symptoms.
The Associated Press reports that a just released study that found that a staggering, two and half million children in the U.S. are being prescribed antipsychotics annually–that’s 40 out of every 1,000 children.
Psychiatric Adverse Events Associated with Drug Treatment of ADHD: Review of Postmarketing Safety Data
"modern pharmacological treatment may be no more beneficial than older ones, despite their added cost."
By denigrading all non-chemical interventions, by focusing narrowly on drugs and drugs alone, psychiatry has signed away its profession status.
Lawsuits & press info RE: SSRI addiction / suicide risk–not scientific literature Fri, 25 Oct To gain knowledge about the scope of a serious threat to public health–i.e., severe adverse drug effects of antidepressant drugs– physicians and consumers must turn to the popular and alternative press, rather than “peer reviewed”…
Abortion Pill Tested in clinical Trials for Severe Depression_NYT Mon, 28 Oct 2002 The New York Times reported that Corcept Therapeutics is testing the controversial abortion pill, Mifepristone (formerly known as RU-486, brand name, Mifreprex), in clinical trials for the treatment of severe depression. The article uncritically transcribed the sponsors’…
Is it ethical to expose healthy children to risks of drug- induced pathology on a speculative, unproven theory?
